Orasure Expects Q3 Revenue of $29.5m-$32.5m While Delaying Inteliquick CT/NG FDA Clearance Beyond 2026

Earnings Call Insights: OraSure Technologies (OSUR) Q2 2026 Management view - âQ2 was another important quarter in OraSure's transformation. We exceeded our revenue guidance, expanded gross margin sequentially, advanced our decentralized diagnostics pipeline... and continu

Earnings Call Insights: OraSure Technologies (OSUR) Q2 2026 Management view – âQ2 was another important quarter in OraSure’s transformation.

We exceeded our revenue guidance, expanded gross margin sequentially, advanced our decentralized diagnostics pipeline… and continue to position the business for sustainable growth and long-term shareholder Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans

Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice.

Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank

Leave a Reply

Your email address will not be published. Required fields are marked *